PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
30 nov. 2021 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce...
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
24 nov. 2021 07h30 HE
|
PharmaTher Holdings Ltd.
Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to treat rare disorders and life-threatening...
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
11 nov. 2021 07h59 HE
|
PharmaTher Holdings Ltd.
Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness.Completing microneedle patch research programs...
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch
03 nov. 2021 07h30 HE
|
PharmaTher Holdings Ltd.
Focusing on partnership model for MicroDose-MN™ and MacroDose-MN™ patches to deliver psychedelics.Creating value and intellectual property protection for psychedelic programs.Providing pathways for...
PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics
01 nov. 2021 09h30 HE
|
PharmaTher Holdings Ltd.
Completing IND-enabling studies with novel microneedle patch for ketamine, psilocybin, MDMA, LSD, and DMT.Expanding research in evaluating ibogaine and mescaline.Aiming for FDA Phase 1 and 2 clinical...
PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022
27 oct. 2021 17h34 HE
|
PharmaTher Holdings Ltd.
TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released its...
World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor
27 oct. 2021 08h49 HE
|
PharmaTher Holdings Ltd.
Focus on expanding the delivery of controlled-substances in a microneedle patch.Evaluating potential uses of a microneedle patch for infectious diseases.Strengthening capabilities in the manufacturing...
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products
19 oct. 2021 07h00 HE
|
PharmaTher Holdings Ltd.
Leading U.S.-based CDMO to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization.Expected FDA clinical and commercial supply in...
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
13 oct. 2021 07h00 HE
|
PharmaTher Holdings Ltd.
Achieving its second FDA orphan drug designation with ketamine.Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation.Seeking to enter Phase 2...
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
06 oct. 2021 09h03 HE
|
PharmaTher Holdings Ltd.
TORONTO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it...